Clinical studies
Studies are essential to clinically validate our innovations and ensure they meet the highest standards of care. They allow us to evaluate the effectiveness and reliability of our devices, optimize our solutions using precise data, demonstrate the advantages of our technologies compared to traditional methods, and assess their medico-economic benefits.
Prospective, multicenter – French study
Bladder cancer
VitaDX International
Phase 1: Develop the most effective image processing algorithm, capable of distinguishing cancerous from non-cancerous urothelial bladder cells. Phase 2: Evaluate the diagnostic performance (sensitivity and specificity) of urine analysis using the VisioCyt® Bladder test."
No reuse in progress
Etude prospective, multicentrique – Européenne
Cancer de la vessie
VitaDX International
Démonstration de l'intérêt de la solution VisioCyt® Bladder par comparaison avec la cytologie urinaire conventionnelle, pour la détection des récidives chez les patients suivis pour des tumeurs de la vessie n’infiltrant pas le muscle à haut et très haut risque.
Pas de réutilisation en cours
Etude prospective, monocentrique – Française
Cancer de la vessie
Institut Paoli-Calmettes et VitaDX International
Mesurer la valeur prédictive négative (VPN) et la sensibilité de l’examen des urines par VisioCyt® Bladder en situation de vie réelle.
Pas de réutilisation en cours
Etude prospective, multicentrique – Française
Cancer de la vessie
Association Française d'Urologie
Approfondir les connaissances sur les tumeurs de vessie et évaluer en vie réelle des biomarqueurs permettant, à terme, de réduire les fibroscopies vésicales inutiles et améliorer le confort des patients.
Pas de réutilisation en cours
Etude prospective, monocentrique – Française
Cancer de la vessie
Institut de Cancérologie de Lorraine
Evaluer la technique de cytologie urinaire VisioCyt® associée à la recherche de mutations de FGFR3 dans les urines pour le diagnostic des cancers de la vessie comparativement à la technique de cytologie urinaire VisioCyt® seule.
Pas de réutilisation en cours
Would you like to participate?
Your participation plays a key role in the development of innovative technologies that improve cancer care.
Data protection
Among the projects listed above, some studies may involve the reuse of data in a new project. If this occurs, you will be informed through the note ‘reuse of data collected from the study’ in the corresponding study sheet.
With your consent, your data may be reused and shared for other health research projects. You will have the option to object to this reuse at any time by contacting VitaDX’s Data Protection Officer.
You have the right to access your data, correct it, and object to its processing in accordance with current regulations.
You also have the following rights:
The right to request a restriction on the processing of your data;
The right to be forgotten and to have your data digitally erased;
The right to set general instructions regarding the retention, deletion, and sharing of your data after your death.
If, after contacting us, you believe your rights are not being respected, you may file a complaint with the CNIL.
In the context of a study, if the processing of your data is based on your consent, you also have the right to data portability.
To exercise your rights, you can send your requests by email to VitaDX’s Data Protection Officer at the following address: [email protected].
